Attralus Closes $56 Million Financing

Feb 6, 2024 Press Releases

PDF Version Proceeds intended to advance clinical pipeline of transformational pan-amyloid removal (PAR) therapeutic candidates Financing led by Alpha Wave Global and also included Bristol Myers Squibb (BMY) SAN FRANCISCO – February 06, 2024 – Attralus, Inc., a...

Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)

Nov 7, 2023 Press Releases

PDF Version 124I-evuzamitide shown to be highly accurate for detection of cardiac amyloid across two independent investigator-initiated studies. 124I-evuzamitide detects multiple types of systemic amyloidosis. 124I-evuzamitide may be more sensitive than standard...

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology

Oct 2, 2023 Press Releases

PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs. AT-01 demonstrated to be highly accurate, with 100% sensitivity for detection of cardiac amyloid, across three independent...

Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis

Dec 19, 2022 Press Releases

PDF Version SAN FRANCISCO – December 19, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the European Commission (EC) and European...

Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate

Oct 17, 2022 Press Releases

PDF Version SAN FRANCISCO, Calif. – October 17, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the first subject has been dosed in...